[{"Assets_0_Q2_USD":204131000.0,"CommonStockSharesOutstanding_0_Q2_shares":293935376.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-34243000.0,"NetIncomeLoss_1_Q2_USD":-34210000.0,"NetIncomeLoss_2_Q2_USD":-58305000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":293662000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":289458000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":293662000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":289458000.0,"StockholdersEquity_0_Q2_USD":-46687000.0,"EarningsPerShareBasic_1_Q2_USD":-0.12,"EarningsPerShareBasic_2_Q2_USD":-0.2,"EarningsPerShareDiluted_1_Q2_USD":-0.12,"EarningsPerShareDiluted_2_Q2_USD":-0.2,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":52643000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":96561000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180801"}]